当前位置: 首页 >> 检索结果
201. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
作者: Ad A van Bodegraven.;Nathalie Bravenboer.;Birgit I Witte.;Gerard Dijkstra.;C Janneke van der Woude.;Pieter C M Stokkers.;Maurice G Russel.;Bas Oldenburg.;Marieke Pierik.;Jan C Roos.;Ruud A van Hogezand.;Vincent K Dik.;Angela E Oostlander.;J Coen Netelenbos.;Lex van de Langerijt.;Daniel W Hommes.;Paul Lips.; .
来源: Gut. 2014年63卷9期1424-30页
Osteoporosis and fractures are frequently encountered in patients with Crohn's disease. In order to prevent fractures, treatment with bone protecting drugs appears warranted early in the course of bone disease when bone loss is not yet prominent. We therefore aimed to demonstrate a beneficial effect on bone density of the bisphosphonate risedronate in osteopenic Crohn's disease patients.
202. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.
作者: Pinelopi Manousou.;Evangelos Cholongitas.;Dimitrios Samonakis.;Emmanuel Tsochatzis.;Alice Corbani.;A P Dhillon.;Janice Davidson.;Manuel Rodríguez-Perálvarez.;D Patch.;J O'Beirne.;D Thorburn.;Tuvinh Luong.;K Rolles.;Brian Davidson.;P A McCormick.;Peter Hayes.;Andrew K Burroughs.
来源: Gut. 2014年63卷6期1005-13页
Early results of a randomised trial showed reduced fibrosis due to recurrent HCV hepatitis with tacrolimus triple therapy (TT) versus monotherapy (MT) following transplantation for HCV cirrhosis. We evaluated the clinical outcomes after a median 8 years of follow-up, including differences in fibrosis assessed by collagen proportionate area (CPA).
203. Waist belt and central obesity cause partial hiatus hernia and short-segment acid reflux in asymptomatic volunteers.
作者: Yeong Yeh Lee.;Angela A Wirz.;James G H Whiting.;Elaine V Robertson.;Donald Smith.;Alexander Weir.;Andrew W Kelman.;Mohammad H Derakhshan.;Kenneth E L McColl.
来源: Gut. 2014年63卷7期1053-60页
There is a high incidence of inflammation and metaplasia at the gastro-oesophageal junction (GOJ) in asymptomatic volunteers. Additionally, the majority of patients with GOJ adenocarcinomas have no history of reflux symptoms. We report the effects of waist belt and increased waist circumference (WC) on the physiology of the GOJ in asymptomatic volunteers.
204. A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants.
作者: Karl G Sylvester.;Xuefeng B Ling.;G Y Liu.;Zachary J Kastenberg.;Jun Ji.;Zhongkai Hu.;Sihua Peng.;Ken Lau.;Fizan Abdullah.;Mary L Brandt.;Richard A Ehrenkranz.;Mary Catherine Harris.;Timothy C Lee.;Joyce Simpson.;Corinna Bowers.;R Lawrence Moss.
来源: Gut. 2014年63卷8期1284-92页
Necrotising enterocolitis (NEC) is a major source of neonatal morbidity and mortality. The management of infants with NEC is currently complicated by our inability to accurately identify those at risk for progression of disease prior to the development of irreversible intestinal necrosis. We hypothesised that integrated analysis of clinical parameters in combination with urine peptide biomarkers would lead to improved prognostic accuracy in the NEC population.
205. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
作者: Ching-Lung Lai.;Sang Hoon Ahn.;Kwan Sik Lee.;Soon Ho Um.;Mong Cho.;Seung Kew Yoon.;Jin-Woo Lee.;Neung Hwa Park.;Young-Oh Kweon.;Joo Hyun Sohn.;Jiyoon Lee.;Jeong-Ae Kim.;Kwang-Hyub Han.;Man-Fung Yuen.
来源: Gut. 2014年63卷6期996-1004页
Besifovir (LB80380) is an acyclic nucleotide phosphonate effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies.
206. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
作者: Laurent Peyrin-Biroulet.;Walter Reinisch.;Jean-Frederic Colombel.;Gerassimos J Mantzaris.;Asher Kornbluth.;Robert Diamond.;Paul Rutgeerts.;Linda K Tang.;Freddy J Cornillie.;William J Sandborn.
来源: Gut. 2014年63卷1期88-95页
The Crohn's Disease Activity Index (CDAI) has been criticised due to heavy weighting on subjective clinical symptoms. C-reactive protein (CRP) and endoscopic lesions are objective measures of inflammation. We investigated the relationships between clinical disease activity, CRP normalisation and mucosal healing in Crohn's disease (CD).
207. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.
作者: David Tooth.;Klara Garsed.;Gulzar Singh.;Luca Marciani.;Ching Lam.;Imogen Fordham.;Annie Fields.;Rawinder Banwait.;Melanie Lingaya.;Robert Layfield.;Maggie Hastings.;Peter Whorwell.;Robin Spiller.
来源: Gut. 2014年63卷5期753-60页
Faecal serine proteases (FSPs) may play a role in irritable bowel syndrome with diarrhoea (IBS-D), but their origin is unclear. We aimed to structurally characterise them and define the impact of colonic cleansing and transit time.
208. Fatigue management in patients with IBD: a randomised controlled trial.
作者: Lauran Vogelaar.;Adriaan van't Spijker.;Reinier Timman.;Antonie J P van Tilburg.;DirkJan Bac.;Ton Vogelaar.;Ernst J Kuipers.;Jan J V van Busschbach.;Christien J van der Woude.
来源: Gut. 2014年63卷6期911-8页
To assess the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD).
209. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
作者: Casper Steenholdt.;Jørn Brynskov.;Ole Østergaard Thomsen.;Lars Kristian Munck.;Jan Fallingborg.;Lisbet Ambrosius Christensen.;Gitte Pedersen.;Jens Kjeldsen.;Bent Ascanius Jacobsen.;Anne Sophie Oxholm.;Jakob Kjellberg.;Klaus Bendtzen.;Mark Andrew Ainsworth.
来源: Gut. 2014年63卷6期919-27页
Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
210. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study.
作者: Su Jin Chung.;Donghee Kim.;Ji Hyun Song.;Hae Yeon Kang.;Goh Eun Chung.;Jeongmin Choi.;Young Sun Kim.;Min Jung Park.;Joo Sung Kim.
来源: Gut. 2014年63卷5期785-91页
Virtual chromoendoscopy (CE) is expected to enhance adenoma yield and reduce variation in performance between colonoscopists. This study aimed to compare the efficacy of narrow band imaging (NBI), flexible spectral imaging CE (FICE) and white light (WL) colonoscopy and their impact for less experienced endoscopists.
211. Endoscopic versus histological characterisation of polyps during screening colonoscopy.
作者: Guido Schachschal.;Michael Mayr.;Andras Treszl.;Klaus Balzer.;Karl Wegscheider.;Jens Aschenbeck.;Alireza Aminalai.;Rolf Drossel.;Andreas Schröder.;Mathias Scheel.;Carl-Hermann Bothe.;Jens-Peter Bruhn.;Wolfgang Burmeister.;Gabriela Stange.;Christina Bähr.;Ralf Kießlich.;Thomas Rösch.
来源: Gut. 2014年63卷3期458-65页
As screening colonoscopy becomes more widespread, the costs for histopathological assessment of resected polyps are rising correspondingly. Reference centres have published highly accurate results for endoscopic polyp classification. Therefore, it has been proposed that, for smaller polyps, the differential diagnosis that guides follow-up recommendations could be based on endoscopy alone.
212. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
作者: Adrian G McNicholl.;Alicia C Marin.;Javier Molina-Infante.;Manuel Castro.;Jesús Barrio.;Julio Ducons.;Xavier Calvet.;Cristobal de la Coba.;Miguel Montoro.;Felipe Bory.;Angeles Perez-Aisa.;Montserrat Forné.;Javier P Gisbert.; .
来源: Gut. 2014年63卷2期244-9页
No trial has compared non-bismuth quadruple 'sequential' and 'concomitant' regimens in settings with increasing clarithromycin rates. The study aims to compare the effectiveness and safety of these therapies for Helicobacter pylori treatment.
213. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
作者: Pieter Dewint.;Bettina E Hansen.;Elke Verhey.;Bas Oldenburg.;Daniel W Hommes.;Marieke Pierik.;Cyriel I J Ponsioen.;Hendrik M van Dullemen.;Maurice Russel.;Ad A van Bodegraven.;C Janneke van der Woude.
来源: Gut. 2014年63卷2期292-9页
To assess whether a combination of adalimumab and ciprofloxacin is superior to adalimumab alone in the treatment of perianal fistulising Crohn's disease (CD).
214. Telephone-based re-education on the day before colonoscopy improves the quality of bowel preparation and the polyp detection rate: a prospective, colonoscopist-blinded, randomised, controlled study.
作者: Xiaodong Liu.;Hui Luo.;Lin Zhang.;Felix W Leung.;Zhiguo Liu.;Xiangping Wang.;Rui Huang.;Na Hui.;Kaichun Wu.;Daiming Fan.;Yanglin Pan.;Xuegang Guo.
来源: Gut. 2014年63卷1期125-30页
Despite advances in bowel preparation methods, the quality of bowel preparation in some patients undergoing colonoscopy remains unsatisfactory. The effect of telephone re-education (TRE) on the day before colonoscopy on the quality of bowel preparation and other outcome measures had not been studied.
215. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
作者: Lloyd Mayer.;William J Sandborn.;Yuriy Stepanov.;Karel Geboes.;Robert Hardi.;Michael Yellin.;Xiaolu Tao.;Li An Xu.;Luisa Salter-Cid.;Sheila Gujrathi.;Richard Aranda.;Allison Y Luo.
来源: Gut. 2014年63卷3期442-50页
Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC.
216. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
作者: Simon P L Travis.;Silvio Danese.;Limas Kupcinskas.;Olga Alexeeva.;Geert D'Haens.;Peter R Gibson.;Luigi Moro.;Richard Jones.;E David Ballard.;Johan Masure.;Matteo Rossini.;William J Sandborn.
来源: Gut. 2014年63卷3期433-41页
Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ulcerative colitis (UC).
217. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
作者: Yaron Rotman.;Mazen Noureddin.;Jordan J Feld.;Jeremie Guedj.;Michael Witthaus.;Hwalih Han.;Yoon J Park.;Su-Hyung Park.;Theo Heller.;Marc G Ghany.;Edward Doo.;Christopher Koh.;Adil Abdalla.;Naveen Gara.;Souvik Sarkar.;Emmanuel Thomas.;Golo Ahlenstiel.;Birgit Edlich.;Rachel Titerence.;Leah Hogdal.;Barbara Rehermann.;Harel Dahari.;Alan S Perelson.;Jay H Hoofnagle.;T Jake Liang.
来源: Gut. 2014年63卷1期161-9页
Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C.
218. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
作者: Pietro Lampertico.;Mauro Viganò.;Giovan Giuseppe Di Costanzo.;Evangelista Sagnelli.;Massimo Fasano.;Vito Di Marco.;Sara Boninsegna.;Patrizia Farci.;Silvia Fargion.;Tiziana Giuberti.;Claudio Iannacone.;Loredana Regep.;Benedetta Massetto.;Floriana Facchetti.;Massimo Colombo.; .
来源: Gut. 2013年62卷2期290-8页
Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.
219. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus.
作者: Alba Rocco.;Debora Compare.;Pietro Coccoli.;Ciro Esposito.;Antimo Di Spirito.;Antonio Barbato.;Pasquale Strazzullo.;Gerardo Nardone.
来源: Gut. 2013年62卷5期766-73页
In vitro, vitamin B12 acts as a natural inhibitor of hepatitis C virus (HCV) replication.
220. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
作者: Volker Heinemann.;Ursula Vehling-Kaiser.;Dirk Waldschmidt.;Erika Kettner.;Angela Märten.;Cornelia Winkelmann.;Stefan Klein.;Georgi Kojouharoff.;Thomas C Gauler.;Ludwig Fischer von Weikersthal.;Michael R Clemens.;Michael Geissler.;Tim F Greten.;Susanna Hegewisch-Becker.;Oleg Rubanov.;Gerold Baake.;Thomas Höhler.;Yon D Ko.;Andreas Jung.;Sascha Neugebauer.;Stefan Boeck.
来源: Gut. 2013年62卷5期751-9页
AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was compared with a reverse experimental sequence of capecitabine/erlotinib followed by gemcitabine.
|